Loading stock data…
Enanta Pharmaceuticals (ENTA)
$13.50-0.58 (-4.12%)
Market ClosedLast close Sep 8
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enanta Pharmaceuticals, Inc. in the Healthcare sector is trading at $13.50 with a market capitalization of $335M. Wall Street consensus targets $19.80 (5 analysts), implying a +46.7% move over the next 12 months. The stock is currently 21% below its 52-week high of $17.15, remaining 0.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +46.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17.16M↓ | $18.61M↑ | $15.13M↓ | $18.31M↑ | $14.93M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.85M↓ | -$11.25M↑ | -$18.39M↑ | -$18.89M↑ | -$24.53M |
| Net Income | -$13.09M↓ | -$11.94M↑ | -$18.70M↓ | -$18.25M↑ | -$22.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$335.27M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-53.17%
Volume
Today's trading volume
157,952
Recent News
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -81.08% and -20.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -337.50% and -45.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +2.17% and -2.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?